These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 15730396

  • 1. Mononuclear cells from patients recovered from cutaneous leishmaniasis respond to Leishmania major amastigote class I nuclease with a predominant Th1-like response.
    Farajnia S, Mahboudi F, Ajdari S, Reiner NE, Kariminia A, Alimohammadian MH.
    Clin Exp Immunol; 2005 Mar; 139(3):498-505. PubMed ID: 15730396
    [Abstract] [Full Text] [Related]

  • 2. T-cell responsiveness of American cutaneous leishmaniasis patients to purified Leishmania pifanoi amastigote antigens and Leishmania braziliensis promastigote antigens: immunologic patterns associated with cure.
    Coutinho SG, Oliveira MP, Da-Cruz AM, De Luca PM, Mendonça SC, Bertho AL, Soong L, McMahon-Pratt D.
    Exp Parasitol; 1996 Nov; 84(2):144-55. PubMed ID: 8932764
    [Abstract] [Full Text] [Related]

  • 3. Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble Leishmania antigen in human cutaneous leishmaniasis.
    Bottrel RL, Dutra WO, Martins FA, Gontijo B, Carvalho E, Barral-Netto M, Barral A, Almeida RP, Mayrink W, Locksley R, Gollob KJ.
    Infect Immun; 2001 May; 69(5):3232-9. PubMed ID: 11292745
    [Abstract] [Full Text] [Related]

  • 4. Leishmanial amastigote antigen P-2 induces major histocompatibility complex class II-dependent natural killer-cell reactivity in cells from healthy donors.
    Nylén S, Maasho K, McMahon-Pratt D, Akuffo H.
    Scand J Immunol; 2004 Mar; 59(3):294-304. PubMed ID: 15030581
    [Abstract] [Full Text] [Related]

  • 5. Immune response to Leishmania antigen in anthroponotic cutaneous leishmaniasis.
    Ajdary S, Riazi-Rad F, Alimohammadian MH, Pakzad SR.
    J Infect; 2009 Aug; 59(2):139-43. PubMed ID: 19560211
    [Abstract] [Full Text] [Related]

  • 6. Th1/Th2 immune responses are associated with active cutaneous leishmaniasis and clinical cure is associated with strong interferon-gamma production.
    Castellano LR, Filho DC, Argiro L, Dessein H, Prata A, Dessein A, Rodrigues V.
    Hum Immunol; 2009 Jun; 70(6):383-90. PubMed ID: 19480861
    [Abstract] [Full Text] [Related]

  • 7. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
    Zadeh-Vakili A, Taheri T, Taslimi Y, Doustdari F, Salmanian AH, Rafati S.
    Vaccine; 2004 May 07; 22(15-16):1930-40. PubMed ID: 15121305
    [Abstract] [Full Text] [Related]

  • 8. Can interferon-gamma and interleukin-10 balance be associated with severity of human Leishmania (Viannia) braziliensis infection?
    Gomes-Silva A, de Cássia Bittar R, Dos Santos Nogueira R, Amato VS, da Silva Mattos M, Oliveira-Neto MP, Coutinho SG, Da-Cruz AM.
    Clin Exp Immunol; 2007 Sep 07; 149(3):440-4. PubMed ID: 17614975
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of vaccination with a combination of Leishmania amastigote antigens and the lipid A-analogue ONO-4007 for immunoprophylaxis and immunotherapy against Leishmania amazonensis infection in a murine model of New World cutaneous leishmaniasis.
    Calvopina M, Barroso PA, Marco JD, Korenaga M, Cooper PJ, Nonaka S, Hashiguchi Y.
    Vaccine; 2006 Jul 07; 24(27-28):5645-52. PubMed ID: 16621179
    [Abstract] [Full Text] [Related]

  • 10. Effect of LACK and KMP11 on IFN-gamma production by peripheral blood mononuclear cells from cutaneous and mucosal leishmaniasis patients.
    Carvalho LP, Passos S, Dutra WO, Soto M, Alonso C, Gollob KJ, Carvalho EM, Ribeiro de Jesus A.
    Scand J Immunol; 2005 Apr 07; 61(4):337-42. PubMed ID: 15853916
    [Abstract] [Full Text] [Related]

  • 11. Interleukin-12 augments a Th1-type immune response manifested as lymphocyte proliferation and interferon gamma production in Leishmania infantum-infected dogs.
    Strauss-Ayali D, Baneth G, Shor S, Okano F, Jaffe CL.
    Int J Parasitol; 2005 Jan 07; 35(1):63-73. PubMed ID: 15619517
    [Abstract] [Full Text] [Related]

  • 12. [Immunopathology of American tegumentary leishmaniasis].
    Castés M, Tapia FJ.
    Acta Cient Venez; 1998 Jan 07; 49(1):42-56. PubMed ID: 10205916
    [Abstract] [Full Text] [Related]

  • 13. Cellular and humoral responses induced by Leishmania histone H2B and its divergent and conserved parts in cutaneous and visceral leishmaniasis patients, respectively.
    Meddeb-Garnaoui A, Toumi A, Ghelis H, Mahjoub M, Louzir H, Chenik M.
    Vaccine; 2010 Feb 17; 28(7):1881-6. PubMed ID: 20005858
    [Abstract] [Full Text] [Related]

  • 14. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40.
    Hernández MX, Barçante TA, Vilela L, Tafuri WL, Afonso LC, Vieira LQ.
    Immunol Lett; 2006 May 15; 105(1):38-47. PubMed ID: 16466810
    [Abstract] [Full Text] [Related]

  • 15. The Leishmania promastigote surface antigen-2 (PSA-2) is specifically recognised by Th1 cells in humans with naturally acquired immunity to L. major.
    Kemp M, Handman E, Kemp K, Ismail A, Mustafa MD, Kordofani AY, Bendtzen K, Kharazmi A, Theander TG.
    FEMS Immunol Med Microbiol; 1998 Mar 15; 20(3):209-18. PubMed ID: 9566492
    [Abstract] [Full Text] [Related]

  • 16. Interleukin (IL)-13 is the predominant Th2 cytokine in localized cutaneous leishmaniasis lesions and renders specific CD4+ T cells unresponsive to IL-12.
    Bourreau E, Prévot G, Pradinaud R, Launois P.
    J Infect Dis; 2001 Mar 15; 183(6):953-9. PubMed ID: 11237813
    [Abstract] [Full Text] [Related]

  • 17. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S, Carrión J, Anderson C, Alonso C, Sacks D, Soto M.
    Infect Immun; 2005 Sep 15; 73(9):5842-52. PubMed ID: 16113303
    [Abstract] [Full Text] [Related]

  • 18. Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients.
    Rafati S, Gholami E, Hassani N, Ghaemimanesh F, Taslimi Y, Taheri T, Soong L.
    Vaccine; 2007 May 22; 25(21):4159-69. PubMed ID: 17395340
    [Abstract] [Full Text] [Related]

  • 19. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12.
    Skeiky YA, Guderian JA, Benson DR, Bacelar O, Carvalho EM, Kubin M, Badaro R, Trinchieri G, Reed SG.
    J Exp Med; 1995 Apr 01; 181(4):1527-37. PubMed ID: 7699334
    [Abstract] [Full Text] [Related]

  • 20. Leishmania major soluble exo-antigens (LmSEAgs) protect neonatal BALB/C mice from a subsequent challenge with L. major and stimulate cytokine production by Leishmania-naïve human peripheral blood mononuclear cells.
    Tonui WK, Titust RG.
    J Parasitol; 2006 Oct 01; 92(5):971-6. PubMed ID: 17152936
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.